SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Granger Christopher B.)
 

Sökning: WFRF:(Granger Christopher B.) > (2020-2024) > In patients with st...

  • White, Harvey D.Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand. (författare)

In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-418944
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-418944URI
  • https://doi.org/10.1016/j.ahj.2020.04.004DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BackgroundIn patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke.MethodsEBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) <100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) < 7% and BP of <130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly.ResultsIn 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model.At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C < 70 mg/dL compared with LDL-C < 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c < 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE.ConclusionsMACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) and even lower with LDL-C < 70 mg/dL. MACE in patients with diabetes was lower with HbA1c < 7%. Achievement of targets is associated with improved patient outcomes.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Stewart, Ralph A. H.Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand. (författare)
  • Dolby, Anthony J.Milpk Hosp, Johannesburg, South Africa. (författare)
  • Stebbins, AmandaDuke Clin Res Inst, Duke Med, Durham, NC USA. (författare)
  • Cannon, Christopher P.Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Harvard Clin Res Inst, Boston, MA 02115 USA. (författare)
  • Budaj, AndrzejGrochowski Hosp, Postgrad Med Sch, Warsaw, Poland. (författare)
  • Linhart, AlesGen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic. (författare)
  • Pais, PremSt Johns Res Inst, Bangalore, Karnataka, India. (författare)
  • Diaz, RafaelInst Cardiovasc Rosario, Estudios Cordiol Latinoamer, Rosario, Argentina. (författare)
  • Steg, Philippe GabrielHop Bichat Claude Bernard, AP HP, Paris, France.;Paris Univ, FACT French Alliance Cardiovasc Trials, INSERM, Paris, France.;Imperial Coll, Natl Heart & Lung Inst, Royal Brampton Hosp, London, England. (författare)
  • Krug-Gourley, SueGlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA. (författare)
  • Granger, Christopher B.Duke Clin Res Inst, Duke Med, Durham, NC USA. (författare)
  • Hochman, Judith S.NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA. (författare)
  • Koenig, WolfgangUniv Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany.;Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.;German Ctr Cardiovasc Res, Heart Alliance, Partner Site Munich, Munich, Germany. (författare)
  • Harrington, Robert A.Stanford Univ, Stanford Ctr Clin Res, Dept Med, Stanford, CA 94305 USA. (författare)
  • Held, Claes,1956-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)clahe947 (författare)
  • Wallentin, Lars,1943-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (författare)
  • Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.Milpk Hosp, Johannesburg, South Africa. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:American Heart Journal: Elsevier BV225, s. 97-1070002-87031097-6744

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy